



DISCLOSURE INFORMATION

INSERT ACTIVITY NAME: INTERNATIONAL SOCIETY OF INNOVATIVE TECHNOLOGIES FOR ENDOCRINE SURGERY

DATES: FEBRUARY 25 & 26, 2022

CITY/STATE (FOR LIVE ACTIVITY): SAN FRANCISCO, CALIFORNIA

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as an “ineligible company”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

Ineligible company: Any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

SPEAKERS / MODERATORS / DISCUSSANTS/AUTHORS	NOTHING TO DISCLOSE	DISCLOSURE		
		COMPANY	ROLE	RECEIVED
<i>Electron Kekebew</i>	X			
<i>Dolores Shoback</i>	X			
<i>Jessica Gosnell</i>	X			
<i>Sam Achilefu</i>		<i>Integro Theranostics</i>	<i>Consultant and Inventor</i>	<i>Consulting Fee</i>
<i>Richard Cha</i>	X			
<i>Giju Thomas</i>		<i>Optosurgical, LLC</i>	<i>Scientific advisor</i>	<i>Ownership interest</i>
<i>Carmen Solorzano</i>	X			
<i>Eren Berber</i>	X			
<i>John Phay</i>		<i>AiBioMed, Inc</i>	<i>Patent license owner</i>	<i>Royalties</i>
<i>Anton Engelsman</i>	X			
<i>Fares Benmiloud</i>	X			
<i>Colleen Kiernan</i>	X			
<i>Marco Demarchi</i>	X			
<i>Paul Gauger</i>		<i>Medtronic</i>	<i>Consultant</i>	<i>Consulting Fee</i>
<i>Michael Bouvet</i>		<i>Stryker</i>	<i>Consultant</i>	<i>Consulting Fee</i>
<i>Saba Balasubramanian</i>	X			
<i>Kerstin Lorenz</i>	X			
<i>Ryan Belcher</i>	X			

<i>Angkoon Anuwong</i>	X			
<i>Hyunsuk Suh</i>	X			
<i>Fernando Dip</i>	X			
<i>Graham Throckmorton</i>	X			
<i>Summer Gibbs</i>		<i>Inherent Targeting, LLC</i>	<i>CSO</i>	<i>Ownership Interest</i>
<i>Milou Noltes</i>	X			
<i>Naira Baregamian</i>	X			
<i>James Koh</i>	X			
<i>Sam Wiseman</i>	X			
<i>Gregory Randolph</i>	X			
<i>Janice Pasieka</i>	X			
<i>James Lee</i>	X			
<i>Chelsey Baldwin</i>	X			
<i>Jonathon O. Russell</i>	X			
<i>Jennifer H. Kuo</i>	X			
<i>Stefano Spiezia</i>	X			
<i>Diego Barbieri</i>	X			
<i>Parker Willmon</i>	X			
<i>Yoseph Kim</i>		<i>Optosurgical, LLC</i>	<i>Chief Operating Officer and R&D Administrator</i>	<i>Salary</i>
<i>Timothy Ullmann</i>	X			
<i>Vidal Fortuny</i>	X			
<i>Stefan Schopft</i>	X			
<i>Patricia Conroy</i>	X			
<i>Taylor St. Amour</i>	X			
PLANNING COMMITTEE	NOTHING TO DISCLOSE	DISCLOSURE		
		COMPANY	ROLE	RECEIVED
<i>Quan-Yang Duh</i>	X			
<i>Anita Mahadevan-Jansen</i>		<i>AlBiomed Inc.</i>	<i>Joint grant with NIH</i>	<i>Equity when acquired by Medtronics</i>
<i>Frédéric Triponez</i>		<i>Medtronics, Fluoptics, Stryker,</i>	<i>Consultant</i>	<i>Honorarium/consultant fees</i>